Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peyman Hadji

Showing results (121-130 of 171) with videos related to

Pageof 18
Sort By:
Journal of Bone Oncology|December 6, 2018
The impact of mammalian target of rapamycin inhibition on bone health in postmenopausal women with hormone receptor-positive advanced breast cancer receiving everolimus plus exemestane in the phase IIIb 4EVER trialPeyman Hadji, Oliver Stoetzer, Thomas Decker, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|September 5, 2008
Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trialJacques P Brown, Richard L Prince, Chad Deal, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 18, 2008
Advancing treatment for metastatic bone cancer: consensus recommendations from the Second Cambridge ConferenceRobert E Coleman, Theresa A Guise, Allan Lipton, et al.
Journal of the National Cancer Institute|February 22, 2013
Effect of everolimus on bone marker levels and progressive disease in bone in BOLERO-2Michael Gnant, Jose Baselga, Hope S Rugo, et al.
JAMA|February 10, 2012
Association between age at diagnosis and disease-specific mortality among postmenopausal women with hormone receptor-positive breast cancerWillemien van de Water, Christos Markopoulos, Cornelis J H van de Velde, et al.
Lancet (London, England)|January 21, 2011
Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trialCornelis J H van de Velde, Daniel Rea, Caroline Seynaeve, et al.
Geburtshilfe Und Frauenheilkunde|December 1, 2018
Update Breast Cancer 2018 (Part 4) - Genomics, Individualized Medicine and Immune Therapies - in the Middle of a New Era: Treatment Strategies for Advanced Breast CancerVolkmar Müller, Achim Wöckel, Michael P Lux, et al.
Geburtshilfe Und Frauenheilkunde|December 1, 2018
Update Breast Cancer 2018 (Part 3) - Genomics, Individualized Medicine and Immune Therapies - in the Middle of a New Era: Prevention and Treatment Strategies for Early Breast CancerAchim Wöckel, Michael P Lux, Wolfgang Janni, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|July 29, 2024
Goal-directed osteoporosis treatment: ASBMR/BHOF task force position statement 2024Felicia Cosman, E Michael Lewiecki, Richard Eastell, et al.
Geburtshilfe Und Frauenheilkunde|December 23, 2017
Update Breast Cancer 2017 - Implementation of Novel TherapiesMichael P Lux, Wolfgang Janni, Andreas D Hartkopf, et al.
Pageof 18

Showing results (121-130 of 171) with videos related to

Sort By:
Pageof 18
Journal of Bone Oncology|December 6, 2018
The impact of mammalian target of rapamycin inhibition on bone health in postmenopausal women with hormone receptor-positive advanced breast cancer receiving everolimus plus exemestane in the phase IIIb 4EVER trialPeyman Hadji, Oliver Stoetzer, Thomas Decker, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|September 5, 2008
Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trialJacques P Brown, Richard L Prince, Chad Deal, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 18, 2008
Advancing treatment for metastatic bone cancer: consensus recommendations from the Second Cambridge ConferenceRobert E Coleman, Theresa A Guise, Allan Lipton, et al.
Journal of the National Cancer Institute|February 22, 2013
Effect of everolimus on bone marker levels and progressive disease in bone in BOLERO-2Michael Gnant, Jose Baselga, Hope S Rugo, et al.
JAMA|February 10, 2012
Association between age at diagnosis and disease-specific mortality among postmenopausal women with hormone receptor-positive breast cancerWillemien van de Water, Christos Markopoulos, Cornelis J H van de Velde, et al.
Lancet (London, England)|January 21, 2011
Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trialCornelis J H van de Velde, Daniel Rea, Caroline Seynaeve, et al.
Geburtshilfe Und Frauenheilkunde|December 1, 2018
Update Breast Cancer 2018 (Part 4) - Genomics, Individualized Medicine and Immune Therapies - in the Middle of a New Era: Treatment Strategies for Advanced Breast CancerVolkmar Müller, Achim Wöckel, Michael P Lux, et al.
Geburtshilfe Und Frauenheilkunde|December 1, 2018
Update Breast Cancer 2018 (Part 3) - Genomics, Individualized Medicine and Immune Therapies - in the Middle of a New Era: Prevention and Treatment Strategies for Early Breast CancerAchim Wöckel, Michael P Lux, Wolfgang Janni, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|July 29, 2024
Goal-directed osteoporosis treatment: ASBMR/BHOF task force position statement 2024Felicia Cosman, E Michael Lewiecki, Richard Eastell, et al.
Geburtshilfe Und Frauenheilkunde|December 23, 2017
Update Breast Cancer 2017 - Implementation of Novel TherapiesMichael P Lux, Wolfgang Janni, Andreas D Hartkopf, et al.
Pageof 18